Biomarkers in oncology
Kounnis V. et al, (2021), Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, 195 - 202
Methodological studies
Azam F. et al, (2021), Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, 227 - 237
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Gray V. et al, (2019), J Natl Cancer Inst, 111, 828 - 836
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Law PJ. et al, (2019), Nat Commun, 10
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
Robles-Zurita J. et al, (2018), Br J Cancer, 119, 1332 - 1338
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ. et al, (2018), Lancet Oncol, 19, 562 - 578
The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.
Huijbers A. et al, (2018), J Surg Oncol, 117, 1043 - 1048
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A. et al, (2018), N Engl J Med, 378, 1177 - 1188
Prognostic markers for colorectal cancer: estimating ploidy and stroma.
Danielsen HE. et al, (2018), Ann Oncol, 29, 616 - 623
Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
Tanskanen T. et al, (2018), Int J Cancer, 142, 540 - 546
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
May-Wilson S. et al, (2017), Eur J Cancer, 84, 228 - 238
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.
Rodriguez-Broadbent H. et al, (2017), Int J Cancer, 140, 2701 - 2708
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Is sidedness prognostically important across all stages of colorectal cancer?
Kerr DJ. et al, (2016), Lancet Oncol, 17, 1480 - 1482
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E. et al, (2016), Lancet Gastroenterol Hepatol, 1, 207 - 216
Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.
Jarvis D. et al, (2016), Br J Cancer, 115, 266 - 272
Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.
Orlando G. et al, (2016), Hum Mol Genet, 25, 2349 - 2359
Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
Colling R. et al, (2015), J Clin Pathol, 68, 1036 - 1039